An evaluation of intravenous immunoglobulin in the treatment of human immunodeficiency virus‐associated thrombocytopenia

Abstract

IVIG consistently raises platelet counts in patients with HIV-associated thrombocytopenia.

Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG

“…43,44 Analysis of platelet counts in anti-TER-119 antibody-treated thrombocytopenic mice indicated that the monoclonal antibody protected against thrombocytopenia for at least 4 days after treatment.…”

Usefulness of a low‐dose intravenous immunoglobulin regimen for the treatment of thrombocytopenia associated with AIDS

“…To evaluate our results we chose the criteria proposing PR not only as an increase > 50 × 10 9 /l in the PC but also raising the initial PC at least twice (raising the PC > 50 × 10 9 /l may be properly called PR for an initial PC < 20 × 10 9 /l but this is not true if the initial PC is 48 × 10 9 /l) [12]. In AIDS-free HIV+ cases, IR to IVIg is fast [33], ranging from 71% to 100% with a failure rate of 29% [13,21,34]. Previous reports described a few AIDS patients [21,23,26,27,35], and based on one patient it was suggested that lower response rates of HIV-Thr to IVIg would more likely be seen in AIDS compared to AIDSfree HIV+ individuals [26].…”

“…Initially, high doses of IVIg for HIV-Thr were successfully used in five-or two-day courses [24,29,34]. Because the half life of IVIg preparations range from 15 to 58 days [49,50], we thought that weekly infusions might maintain adequate plasma levels of Ig.…”

Recommendations for the use of immunoglobulin therapy for immunomodulation and antibody replacement

“…IV Ig is indicated in patients with thrombocytopenia secondary to HIV infection unresponsive to antiretroviral therapy, and the management should not differ from that for the idiopathic form. [21,22] Immune red cell destruction has also been a focus of interest for immunoglobulin therapy. Controlled studies have Key steps in modern manufacturing focus on: (i) the removal of substances associated with side-effects, e.g.…”